NIH grant to compare ES and iPS cells A major question in stem
cell biology is whether human induced pluripotent stem cells
(iPS cells) are the functional and molecular equivalent to human
embryonic stem cells (ES cells), and whether they can serve as
an effective resource for research and for cell-based therapies.
Under a new, $1.7 million Recovery Act grant from the National
Institutes of Health, the laboratory of George Q. Daley, MD,
PhD, will comprehensively compare iPS cells with ES cells
isolated from embryos, ES cells produced through nuclear
transfer, and ES cells created through parthenogenesis. From
fishtank to bedside: turbo-charging blood stem cell production A
new drug that boosts numbers of blood stem cells, originally
discovered in zebrafish in the Boston Children’s Hospital
laboratory of Leonard Zon, MD, goes to clinical trial in
patients with leukemia and lymphoma. Read more from Dana Farber
Cancer Institute, one of the sites of the trial, which is
sponsored by Fate Therapeutics. For more on